Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Generation Bio ( (GBIO) ) has issued an announcement.
Generation Bio announced significant changes in its leadership team and a strategic reorganization to focus on developing siRNA therapeutics using its ctLNP technology, targeting T cell-driven autoimmune diseases. The company plans to reduce its workforce by 20% to optimize resources for clinical development and aims to submit its first investigational new drug application by the second half of 2026, while maintaining a cash runway until the second half of 2027.
More about Generation Bio
Generation Bio is a biotechnology company focused on developing therapeutics for T cell-driven autoimmune diseases. The company leverages its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA in vivo, aiming to modulate T cell activity involved in inflammation and tissue destruction, potentially unlocking treatments for targets that are difficult to address with existing drugs.
YTD Price Performance: 3.60%
Average Trading Volume: 254,309
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $76.81M
For a thorough assessment of GBIO stock, go to TipRanks’ Stock Analysis page.
